Plasma Gelsolin's Biological Role: Protect and Defend
Plasma gelsolin (pGSN) is an ancient, highly conserved human protein that is a highly abundant plasma protein in healthy individuals. Its role is to keep inflammation localized to the site of injury and to boost the body’s ability to clear pathogens.
It regulates the pathogen clearance by enhancing NOS3 and scavenger receptor activity in macrophages and thereby improves antimicrobial defense in multiple gram positive and negative resistant and sensitive bacterial strains, as well as pneumonia secondary to influenza.
Plasma gelsolin’s efficacy is not limited to bacterial infection. Its non-immunosuppressive anti-inflammatory addresses the inflammatory component of infection, including severe flu, as well as multiple inflammatory, autoimmune and degenerative diseases.
Key Component of Innate Immunity:
Macrophage Regulation by Plasma Gelsolin
NORMAL CIRCUMSTANCES
Macrophage receptor with collagenous structure (MARCO) binds with pathogens. Macrophage absorbs and destroys them, maintaining homeostasis.
INJURY OR INFECTION
Actin released from cellular injury or infection binds to MARCO preventing it from binding with pathogens. Without your macrophage defense system, pathogens can build up making a small infection severe.
PLASMA GELSOLIN IN ACTION
Plasma Gelsolin overcomes the actin inhibition which increases pathogen binding and uptake. Plasma Gelsolin also stimulates NOS3 activation via Akt phosphorylation to improve killing of the pathogen inside the cell.
Efficacy Demonstrated in >20 Models in Independent Labs
Enhanced Microbial Uptake and Killing in Human Alveolar Macrophages
Gram Positive
Gram Negative
Influenza
Infectious Peritonitis
INFECTION
Inflammation/CV/Metabolic
Ischemic Stroke Model
Inflammatory Bowel Disease
Diabetes Type 2: Multiple Models
Pain: Central/Periheral Models
Alzheimer’s Disease
Multiple Sclerosis (EAE)
Neuroinflammation
Neurological
INJURY/TRAUMA
Burns – Lung Microvascular Permeability
Radiation Exposure
Hyperoxia Acute Lung Injury
Collaborating With Over 20 Institutions Worldwide
BOSTON, MA
Harvard TH Chan School of Public Health
Brigham and Womens Hospital
Beth Israel Deaconess Hospital
Mass General Hospital
BETHESDA/BALTIMORE, MD
NIA - National Institute on Aging
University of Maryland
NIAID - National Institute of Allergy and Infectious Disease
CHICAGO, IL
Feinberg School of Medicine, Northwestern University
PENNSYLVANIA
University of Pennsylvania, Philadelphia
University of Pittsburgh, Pittsburgh
TENNESSEE
St. Jude Children's Research Hospital, Memphis
Vanderbilt University School of Medicine, Nashville
MICHIGAN
Central Michigan University
CALIFORNIA
University of California San Diego
NEW YORK
Weill Cornell Medical Center, New York City
Syracuse VA Medical Center, Syracuse
TORONTO
University of Toronto
KENTUCKY
University of Louisville
FINLAND
University of Helsinki, Helsinki
POLAND
Medical University of Bialystok, Bialystok
SOUTH KOREA
Hangyang University, Seoul
BioAegis has established collaborations with a number of leading investigators. These collaborations enhance the ability to recognize additional commercial opportunities, extend the research effort that is ongoing in its own laboratory, and refine and drive current programs forward.
